Needham Maintains Buy on Cormedix, Raises Price Target to $14
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price target from $12 to $14.
Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price target from $12 to $14.